Articlenpj drug discovery2026
AI-guided competitive docking for virtual screening and compound efficacy prediction.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CAFE: A Co-folding Approach for Fragment Exploration of Allosteric and Cryptic Binding Sites.bioRxiv : the preprint server for biology · 2026Article
- Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling.npj drug discovery · 2026Article
- Formulation development and preliminary biological evaluation of a menthol modified thermoresponsive tamoxifen sol-gel.Medical oncology (Northwood, London, England) · 2026Article
- Open-Source Molecular Docking and AI-Augmented Structure-Based Drug Design: Current Workflows, Challenges, and Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Machine learning has revolutionized protein structure and interaction prediction, yet its full potential for drug discovery is still emerging. In this study, we show that denoise diffusion-based co-folding methods-such as AlphaFold3 and Boltz-1/2-not only achieve highly accurate protein-ligand interaction predictions but can also separate active compounds from inactive ones. We introduce a simple and effective strategy, pairwise competitive docking, which ranks candidate molecules by directly comparing their relative binding to a protein's target site. Applied to 17 protein benchmark systems, the method generated rankings consistent with experimental trends, although the degree of agreement varied considerably by system, with concordance indices ranging from 0.52 (indicating no meaningful correlation) to 0.89 (indicating strong correlation). Notably, our rankings showed strong agreement with Boltz-2 affinity predictions, positioning our method as a practical alternative for inhibitor prioritization. Finally, we show how pairwise competitive docking can accelerate the identification of promising hits within a large chemical library and guide the de novo design of inhibitors with improved predicted potency. Collectively, these findings highlight how modern machine-learning models can make structure-based drug design faster, more reliable, and more cost-effective than relying solely on experimental workflows.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.